All In Biotech

Free tool

FAERS Monitor: Anoro Ellipta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203975 or its brand name (Anoro Ellipta, Umeclidinium Bromide, Vilanterol Trifenatate). Reports on generic versions are filed under their own applications.

Reports

16,834

Serious

5,911

35% of reports

Hospitalization

3,054

Death reported

856

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea2,391
  • wrong technique in device usage process1,681
  • drug ineffective1,639
  • product complaint1,219
  • cough1,116
  • product dose omission issue930
  • pneumonia684
  • chronic obstructive pulmonary disease637
  • condition aggravated521
  • drug dispensing error496
  • off label use491
  • death478
  • drug dose omission472
  • product use in unapproved indication458
  • fatigue457

Reports by year received

View as table
YearReports
20121
20135
2014267
20151,005
20161,554
20171,660
20182,336
20192,296
20202,026
20211,290
2022981
2023947
2024981
2025926
2026559

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product complaintSignal1,21963.159.770,938
wrong technique in device usage processSignal1,68146.644.572,437
drug dispensing errorSignal49641.938.419,128
chronic obstructive pulmonary diseaseSignal63715.414.38,497
dyspnoeaSignal2,3915.35.18,521
coughSignal1,1165.04.73,588
product dose omission issueSignal9304.03.72,078
drug dose omissionSignal4723.63.3877
pneumoniaSignal6842.62.5706
product use in unapproved indicationSignal4582.32.1343
condition aggravatedSignal5212.12.0321
drug ineffective1,6391.61.5345
fatigue4570.70.746
off label use4910.70.665
death4780.70.667

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.